Search

Your search keyword '"Vivien, E."' showing total 22 results
Start Over Author "Vivien, E." Publisher american association for cancer research (aacr)
22 results on '"Vivien, E."'

1. Supplementary Table 1 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Tozer, Gillian M., primary, Akerman, Simon, primary, Cross, Neil A., primary, Barber, Paul R., primary, Björndahl, Meit A., primary, Greco, Olga, primary, Harris, Sheila, primary, Hill, Sally A., primary, Honess, Davina J., primary, Ireson, Christopher R., primary, Pettyjohn, Katie L., primary, Prise, Vivien E., primary, Reyes-Aldasoro, Constantino C., primary, Ruhrberg, Christiana, primary, Shima, David T., primary, and Kanthou, Chryso, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 1 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Tozer, Gillian M., primary, Akerman, Simon, primary, Cross, Neil A., primary, Barber, Paul R., primary, Björndahl, Meit A., primary, Greco, Olga, primary, Harris, Sheila, primary, Hill, Sally A., primary, Honess, Davina J., primary, Ireson, Christopher R., primary, Pettyjohn, Katie L., primary, Prise, Vivien E., primary, Reyes-Aldasoro, Constantino C., primary, Ruhrberg, Christiana, primary, Shima, David T., primary, and Kanthou, Chryso, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figures, Table and Movie Legend from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Tozer, Gillian M., primary, Akerman, Simon, primary, Cross, Neil A., primary, Barber, Paul R., primary, Björndahl, Meit A., primary, Greco, Olga, primary, Harris, Sheila, primary, Hill, Sally A., primary, Honess, Davina J., primary, Ireson, Christopher R., primary, Pettyjohn, Katie L., primary, Prise, Vivien E., primary, Reyes-Aldasoro, Constantino C., primary, Ruhrberg, Christiana, primary, Shima, David T., primary, and Kanthou, Chryso, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 2 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Tozer, Gillian M., primary, Akerman, Simon, primary, Cross, Neil A., primary, Barber, Paul R., primary, Björndahl, Meit A., primary, Greco, Olga, primary, Harris, Sheila, primary, Hill, Sally A., primary, Honess, Davina J., primary, Ireson, Christopher R., primary, Pettyjohn, Katie L., primary, Prise, Vivien E., primary, Reyes-Aldasoro, Constantino C., primary, Ruhrberg, Christiana, primary, Shima, David T., primary, and Kanthou, Chryso, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Movie from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Tozer, Gillian M., primary, Akerman, Simon, primary, Cross, Neil A., primary, Barber, Paul R., primary, Björndahl, Meit A., primary, Greco, Olga, primary, Harris, Sheila, primary, Hill, Sally A., primary, Honess, Davina J., primary, Ireson, Christopher R., primary, Pettyjohn, Katie L., primary, Prise, Vivien E., primary, Reyes-Aldasoro, Constantino C., primary, Ruhrberg, Christiana, primary, Shima, David T., primary, and Kanthou, Chryso, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 4 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Tozer, Gillian M., primary, Akerman, Simon, primary, Cross, Neil A., primary, Barber, Paul R., primary, Björndahl, Meit A., primary, Greco, Olga, primary, Harris, Sheila, primary, Hill, Sally A., primary, Honess, Davina J., primary, Ireson, Christopher R., primary, Pettyjohn, Katie L., primary, Prise, Vivien E., primary, Reyes-Aldasoro, Constantino C., primary, Ruhrberg, Christiana, primary, Shima, David T., primary, and Kanthou, Chryso, primary

Published
2023
Full Text
View/download PDF

7. Data from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Tozer, Gillian M., primary, Akerman, Simon, primary, Cross, Neil A., primary, Barber, Paul R., primary, Björndahl, Meit A., primary, Greco, Olga, primary, Harris, Sheila, primary, Hill, Sally A., primary, Honess, Davina J., primary, Ireson, Christopher R., primary, Pettyjohn, Katie L., primary, Prise, Vivien E., primary, Reyes-Aldasoro, Constantino C., primary, Ruhrberg, Christiana, primary, Shima, David T., primary, and Kanthou, Chryso, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 3 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Tozer, Gillian M., primary, Akerman, Simon, primary, Cross, Neil A., primary, Barber, Paul R., primary, Björndahl, Meit A., primary, Greco, Olga, primary, Harris, Sheila, primary, Hill, Sally A., primary, Honess, Davina J., primary, Ireson, Christopher R., primary, Pettyjohn, Katie L., primary, Prise, Vivien E., primary, Reyes-Aldasoro, Constantino C., primary, Ruhrberg, Christiana, primary, Shima, David T., primary, and Kanthou, Chryso, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 5 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Tozer, Gillian M., primary, Akerman, Simon, primary, Cross, Neil A., primary, Barber, Paul R., primary, Björndahl, Meit A., primary, Greco, Olga, primary, Harris, Sheila, primary, Hill, Sally A., primary, Honess, Davina J., primary, Ireson, Christopher R., primary, Pettyjohn, Katie L., primary, Prise, Vivien E., primary, Reyes-Aldasoro, Constantino C., primary, Ruhrberg, Christiana, primary, Shima, David T., primary, and Kanthou, Chryso, primary

Published
2023
Full Text
View/download PDF

10. Data from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Chryso Kanthou, David T. Shima, Christiana Ruhrberg, Constantino C. Reyes-Aldasoro, Vivien E. Prise, Katie L. Pettyjohn, Christopher R. Ireson, Davina J. Honess, Sally A. Hill, Sheila Harris, Olga Greco, Meit A. Björndahl, Paul R. Barber, Neil A. Cross, Simon Akerman, and Gillian M. Tozer

Abstract

Tubulin-binding vascular-disrupting agents (VDA) are currently in clinical trials for cancer therapy but the factors that influence tumor susceptibility to these agents are poorly understood. We evaluated the consequences of modifying tumor vascular morphology and function on vascular and therapeutic response to combretastatin-A4 3-O-phosphate (CA-4-P), which was chosen as a model VDA. Mouse fibrosarcoma cell lines that are capable of expressing all vascular endothelial growth factor (VEGF) isoforms (control) or only single isoforms of VEGF (VEGF120, VEGF164, or VEGF188) were developed under endogenous VEGF promoter control. Once tumors were established, VEGF isoform expression did not affect growth or blood flow rate. However, VEGF188 was uniquely associated with tumor vascular maturity, resistance to hemorrhage, and resistance to CA-4-P. Pericyte staining was much greater in VEGF188 and control tumors than in VEGF120 and VEGF164 tumors. Vascular volume was highest in VEGF120 and control tumors (CD31 staining) but total vascular length was highest in VEGF188 tumors, reflecting very narrow vessels forming complex vascular networks. I.v. administered 40 kDa FITC-dextran leaked slowly from the vasculature of VEGF188 tumors compared with VEGF120 tumors. Intravital microscopy measurements of vascular length and RBC velocity showed that CA-4-P produced significantly more vascular damage in VEGF120 and VEGF164 tumors than in VEGF188 and control tumors. Importantly, this translated into a similar differential in therapeutic response, as determined by tumor growth delay. Results imply differences in signaling pathways between VEGF isoforms and suggest that VEGF isoforms might be useful in vascular-disrupting cancer therapy to predict tumor susceptibility to VDAs. [Cancer Res 2008;68(7):2301–11]

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 3 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Chryso Kanthou, David T. Shima, Christiana Ruhrberg, Constantino C. Reyes-Aldasoro, Vivien E. Prise, Katie L. Pettyjohn, Christopher R. Ireson, Davina J. Honess, Sally A. Hill, Sheila Harris, Olga Greco, Meit A. Björndahl, Paul R. Barber, Neil A. Cross, Simon Akerman, and Gillian M. Tozer

Abstract

Supplementary Figure 3 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Published
2023
Full Text
View/download PDF

12. Supplementary Table 1 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Chryso Kanthou, David T. Shima, Christiana Ruhrberg, Constantino C. Reyes-Aldasoro, Vivien E. Prise, Katie L. Pettyjohn, Christopher R. Ireson, Davina J. Honess, Sally A. Hill, Sheila Harris, Olga Greco, Meit A. Björndahl, Paul R. Barber, Neil A. Cross, Simon Akerman, and Gillian M. Tozer

Abstract

Supplementary Table 1 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 4 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Chryso Kanthou, David T. Shima, Christiana Ruhrberg, Constantino C. Reyes-Aldasoro, Vivien E. Prise, Katie L. Pettyjohn, Christopher R. Ireson, Davina J. Honess, Sally A. Hill, Sheila Harris, Olga Greco, Meit A. Björndahl, Paul R. Barber, Neil A. Cross, Simon Akerman, and Gillian M. Tozer

Abstract

Supplementary Figure 4 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 5 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Chryso Kanthou, David T. Shima, Christiana Ruhrberg, Constantino C. Reyes-Aldasoro, Vivien E. Prise, Katie L. Pettyjohn, Christopher R. Ireson, Davina J. Honess, Sally A. Hill, Sheila Harris, Olga Greco, Meit A. Björndahl, Paul R. Barber, Neil A. Cross, Simon Akerman, and Gillian M. Tozer

Abstract

Supplementary Figure 5 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 2 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Chryso Kanthou, David T. Shima, Christiana Ruhrberg, Constantino C. Reyes-Aldasoro, Vivien E. Prise, Katie L. Pettyjohn, Christopher R. Ireson, Davina J. Honess, Sally A. Hill, Sheila Harris, Olga Greco, Meit A. Björndahl, Paul R. Barber, Neil A. Cross, Simon Akerman, and Gillian M. Tozer

Abstract

Supplementary Figure 2 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Published
2023
Full Text
View/download PDF

16. Supplementary Figures, Table and Movie Legend from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Chryso Kanthou, David T. Shima, Christiana Ruhrberg, Constantino C. Reyes-Aldasoro, Vivien E. Prise, Katie L. Pettyjohn, Christopher R. Ireson, Davina J. Honess, Sally A. Hill, Sheila Harris, Olga Greco, Meit A. Björndahl, Paul R. Barber, Neil A. Cross, Simon Akerman, and Gillian M. Tozer

Abstract

Supplementary Figures, Table and Movie Legend from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 1 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Chryso Kanthou, David T. Shima, Christiana Ruhrberg, Constantino C. Reyes-Aldasoro, Vivien E. Prise, Katie L. Pettyjohn, Christopher R. Ireson, Davina J. Honess, Sally A. Hill, Sheila Harris, Olga Greco, Meit A. Björndahl, Paul R. Barber, Neil A. Cross, Simon Akerman, and Gillian M. Tozer

Abstract

Supplementary Figure 1 from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Published
2023
Full Text
View/download PDF

18. Supplementary Movie from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Chryso Kanthou, David T. Shima, Christiana Ruhrberg, Constantino C. Reyes-Aldasoro, Vivien E. Prise, Katie L. Pettyjohn, Christopher R. Ireson, Davina J. Honess, Sally A. Hill, Sheila Harris, Olga Greco, Meit A. Björndahl, Paul R. Barber, Neil A. Cross, Simon Akerman, and Gillian M. Tozer

Abstract

Supplementary Movie from Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Published
2023
Full Text
View/download PDF

19. Nitric Oxide Synthase Inhibition Enhances the Tumor Vascular-Damaging Effects of Combretastatin A-4 3-O-Phosphate at Clinically Relevant Doses

Author

Sally A. Hill, Ian D. Wilson, Shaoping Xie, Gemma Lewis, Gillian M. Tozer, and Vivien E. Prise

Subjects
Male, Cancer Research, medicine.medical_specialty, Time Factors, Necrosis, Cell Survival, Nitroarginine, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Stilbenes, medicine, Animals, Enzyme Inhibitors, Combretastatin, Combretastatin A-4, Dose-Response Relationship, Drug, biology, Drug Synergism, Rats, Inbred Strains, Antineoplastic Agents, Phytogenic, Rats, Tumor Burden, Nitric oxide synthase, Endocrinology, medicine.anatomical_structure, Oncology, chemistry, biology.protein, Vascular resistance, Blood Vessels, Tumor necrosis factor alpha, Sarcoma, Experimental, Nitric Oxide Synthase, medicine.symptom, Blood Flow Velocity, Blood vessel
Abstract

Purpose: The therapeutic potential of combining the prototype tumor vascular-disrupting agent combretastatin A-4 3-O-phosphate (CA-4-P) with systemic nitric oxide synthase (NOS) inhibition was investigated preclinically. Experimental Design: Vascular response (uptake of 125I-labeled iodoantipyrine; laser Doppler flowmetry) and tumor response (histologic necrosis; cytotoxicity and growth delay) were determined. Results: Inducible NOS selective inhibitors had no effect on blood flow in the P22 rat sarcoma. In contrast, the non–isoform-specific NOS inhibitor Nω-nitro- l-arginine (l-NNA; 1 and 10 mg/kg i.v. or chronic 0.1 or 0.3 mg/mL in drinking water) decreased the P22 blood flow rate selectively down to 36% of control at 1 hour but did not induce tumor necrosis at 24 hours. CA-4-P, at clinically relevant doses, decreased the P22 blood flow rate down to 6% of control at 1 hour for 3 mg/kg but with no necrosis induction. However, l-NNA administration enhanced both CA-4-P–induced tumor vascular resistance at 1 hour (chronic l-NNA administration) and necrosis at 24 hours, with 45% or 80% necrosis for 3 and 10 mg/kg CA-4-P, respectively. Bolus l-NNA given 3 hours after CA-4-P was the most effective cytotoxic schedule in the CaNT mouse mammary carcinoma, implicating a particular enhancement by l-NNA of the downstream consequences of CA-4-P treatment. Repeated dosing of l-NNA with CA-4-P produced enhanced growth delay over either treatment alone in P22, CaNT, and spontaneous T138 mouse mammary tumors, which represented a true therapeutic enhancement. Conclusions: The combination of NOS inhibition with CA-4-P is a promising approach for targeting tumor vasculature, with relevance for similar vascular-disrupting agents in development.

Published
2009
Full Text
View/download PDF

20. Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Christopher R. Ireson, Sally A. Hill, Sheila Harris, Meit A. Björndahl, Vivien E. Prise, Olga Greco, Constantino Carlos Reyes-Aldasoro, Katie L. Pettyjohn, David T. Shima, Paul R. Barber, Simon Akerman, Neil Cross, Davina J. Honess, Gillian M. Tozer, Chryso Kanthou, and Christiana Ruhrberg

Subjects
Vascular Endothelial Growth Factor A, CD31, Cancer Research, Pathology, medicine.medical_specialty, Angiogenesis, Fibrosarcoma, Angiogenesis Inhibitors, Enzyme-Linked Immunosorbent Assay, Mice, SCID, Biology, RC0254, Mice, chemistry.chemical_compound, Cell Line, Tumor, Stilbenes, medicine, Animals, Protein Isoforms, RNA, Messenger, T1, Neovascularization, Pathologic, Immunohistochemistry, Vascular endothelial growth factor, Vascular endothelial growth factor B, Vascular endothelial growth factor A, medicine.anatomical_structure, Oncology, chemistry, Blood vessel maturation, Female, Pericyte, Blood vessel
Abstract

Tubulin-binding vascular-disrupting agents (VDA) are currently in clinical trials for cancer therapy but the factors that influence tumor susceptibility to these agents are poorly understood. We evaluated the consequences of modifying tumor vascular morphology and function on vascular and therapeutic response to combretastatin-A4 3-O-phosphate (CA-4-P), which was chosen as a model VDA. Mouse fibrosarcoma cell lines that are capable of expressing all vascular endothelial growth factor (VEGF) isoforms (control) or only single isoforms of VEGF (VEGF120, VEGF164, or VEGF188) were developed under endogenous VEGF promoter control. Once tumors were established, VEGF isoform expression did not affect growth or blood flow rate. However, VEGF188 was uniquely associated with tumor vascular maturity, resistance to hemorrhage, and resistance to CA-4-P. Pericyte staining was much greater in VEGF188 and control tumors than in VEGF120 and VEGF164 tumors. Vascular volume was highest in VEGF120 and control tumors (CD31 staining) but total vascular length was highest in VEGF188 tumors, reflecting very narrow vessels forming complex vascular networks. I.v. administered 40 kDa FITC-dextran leaked slowly from the vasculature of VEGF188 tumors compared with VEGF120 tumors. Intravital microscopy measurements of vascular length and RBC velocity showed that CA-4-P produced significantly more vascular damage in VEGF120 and VEGF164 tumors than in VEGF188 and control tumors. Importantly, this translated into a similar differential in therapeutic response, as determined by tumor growth delay. Results imply differences in signaling pathways between VEGF isoforms and suggest that VEGF isoforms might be useful in vascular-disrupting cancer therapy to predict tumor susceptibility to VDAs. [Cancer Res 2008;68(7):2301–11]

Published
2008
Full Text
View/download PDF

22. Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Author

Tozer, Gillian M., primary, Akerman, Simon, additional, Cross, Neil A., additional, Barber, Paul R., additional, Björndahl, Meit A., additional, Greco, Olga, additional, Harris, Sheila, additional, Hill, Sally A., additional, Honess, Davina J., additional, Ireson, Christopher R., additional, Pettyjohn, Katie L., additional, Prise, Vivien E., additional, Reyes-Aldasoro, Constantino C., additional, Ruhrberg, Christiana, additional, Shima, David T., additional, and Kanthou, Chryso, additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results